UBS AM’s Vanda Pharmaceuticals VNDA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | – | Sell |
-17,565
| Closed | -$82.9K | – | 2619 |
|
|
2025
Q2 | $82.9K | Buy |
+17,565
| New | +$76.8K | ﹤0.01% | 2595 |
|
|
2023
Q4 | – | Sell |
-71,000
| Closed | -$307K | – | 2606 |
|
|
2023
Q3 | $307K | Sell |
71,000
-12,309
| -15% | -$68.4K | ﹤0.01% | 2428 |
|
|
2023
Q2 | $566K | Hold |
83,309
| – | – | ﹤0.01% | 2274 |
|
|
2023
Q1 | $566K | Buy |
83,309
+23,159
| +39% | +$163K | ﹤0.01% | 2274 |
|
|
2022
Q4 | $445K | Hold |
60,150
| – | – | ﹤0.01% | 2220 |
|
|
2022
Q3 | $594K | Hold |
60,150
| – | – | ﹤0.01% | 2266 |
|
|
2022
Q2 | $656K | Hold |
60,150
| – | – | ﹤0.01% | 2172 |
|
|
2022
Q1 | $680K | Hold |
60,150
| – | – | ﹤0.01% | 2335 |
|
|
2021
Q4 | $944K | Hold |
60,150
| – | – | ﹤0.01% | 2242 |
|
|
2021
Q3 | $1.03M | Buy |
60,150
+12,309
| +26% | +$216K | ﹤0.01% | 2148 |
|
|
2021
Q2 | $1.03M | Buy |
47,841
+6,582
| +16% | +$118K | ﹤0.01% | 2205 |
|
|
2021
Q1 | $620K | Sell |
41,259
-6,591
| -14% | -$107K | ﹤0.01% | 2308 |
|
|
2020
Q4 | $629K | Hold |
47,850
| – | – | ﹤0.01% | 2208 |
|
|
2020
Q3 | $462K | Hold |
47,850
| – | – | ﹤0.01% | 2180 |
|
|
2020
Q2 | $547K | Buy |
47,850
+2,814
| +6% | +$31.9K | ﹤0.01% | 2084 |
|
|
2020
Q1 | $467K | Buy |
45,036
+5,293
| +13% | +$65.6K | ﹤0.01% | 2002 |
|
|
2019
Q4 | $652K | Sell |
39,743
-4,913
| -11% | -$74.3K | ﹤0.01% | 2121 |
|
|
2019
Q3 | $593K | Buy |
44,656
+10,329
| +30% | +$144K | ﹤0.01% | 2199 |
|
|
2019
Q2 | $484K | Buy |
34,327
+16,171
| +89% | +$257K | ﹤0.01% | 2226 |
|
|
2019
Q1 | $334K | Buy |
18,156
+4,732
| +35% | +$108K | ﹤0.01% | 2270 |
|
|
2018
Q4 | $351K | Buy |
+13,424
| New | +$316K | ﹤0.01% | 2139 |
|
|
2016
Q4 | – | Sell |
-16,300
| Closed | -$271K | – | 2667 |
|
|
2016
Q3 | $271K | Hold |
16,300
| – | – | ﹤0.01% | 2320 |
|
|
2016
Q2 | $182K | Buy |
16,300
+1,600
| +11% | +$15.5K | ﹤0.01% | 2472 |
|
|
2016
Q1 | $123K | Sell |
14,700
-15,700
| -52% | -$129K | ﹤0.01% | 2540 |
|
|
2015
Q4 | $283K | Sell |
30,400
-1,400
| -4% | -$14K | ﹤0.01% | 2366 |
|
|
2015
Q3 | $358K | Buy |
31,800
+1,900
| +6% | +$23.2K | ﹤0.01% | 2193 |
|
|
2015
Q2 | $379K | Buy |
29,900
+1,400
| +5% | +$15.1K | ﹤0.01% | 2218 |
|
|
2015
Q1 | $265K | Buy |
28,500
+1,000
| +4% | +$11.3K | ﹤0.01% | 2340 |
|
|
2014
Q4 | $394K | Buy |
27,500
+15,600
| +131% | +$185K | ﹤0.01% | 2067 |
|
|
2014
Q3 | $124K | Hold |
11,900
| – | – | ﹤0.01% | 2476 |
|
|
2014
Q2 | $193K | Buy |
+11,900
| New | +$158K | ﹤0.01% | 2424 |
|
Other funds holding VNDA
TCM
KAM
UBS AM's VNDA Position: Q3 2025 in Review
UBS AM sold out of Vanda Pharmaceuticals (VNDA) in Q3 2025, closing a stake of 17,565 shares — an estimated $82.9K sold.
UBS AM first reported a position in VNDA in Q2 2014 and held it in 31 quarters. The position peaked at $1.03M in Q3 2021. 150 funds tracked by Wall St. Rank hold VNDA as of Q3 2025.
- UBS AM reported no remaining Vanda Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
- UBS AM sold 17,565 Vanda Pharmaceuticals shares in Q3 2025, an estimated $82.9K.
- UBS AM first reported a position in Vanda Pharmaceuticals in Q2 2014 and held it in 31 quarters.
- UBS AM's Vanda Pharmaceuticals position peaked at $1.03M in Q3 2021.
- 150 funds tracked by Wall St. Rank held Vanda Pharmaceuticals as of Q3 2025.
Based on UBS AM's 13F filing for Q3 2025, filed 14 Nov 2025.